Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise
Agenus (AGEN) is back in focus after fresh Phase 1b data on its botensilimab plus balstilimab regimen in refractory microsatellite stable metastatic colorectal cancer, as well as an oversubscribed private placement tied to its planned ROBBIN Phase 3 trial.
See our latest analysis for Agenus.
Agenus has been highly volatile, with the share price return up 45.1% over the past week and 57.3% year to date, but the 1 year total shareholder return is still down 18.3% and the 5 year total shareholder return is down 95.3%, which suggests recent momentum is rebuilding after a long period of weak overall investor outcomes.
If you are looking beyond Agenus for other ideas in high growth areas, this is a good time to see what is moving in 40 healthcare AI stocks
After a 45.1% move in a week and a market cap of about $254.9 million sitting against analyst estimates that average $30 per share, the gap between Agenus' price and implied fair value is hard to ignore. So what are you really paying for here?
Most Popular Narrative: 83.1% Undervalued
The most followed narrative on Agenus pitches a fair value of $30 per share against the last close of $5.08. It frames a large gap that hinges on how its colorectal cancer program plays out.
Exceptional enthusiasm and rapid enrollment in global clinical trials, driven by both investigator/patient demand and international collaborations (Canada, Australia, France), indicate compelling product-market fit and should enable efficient trial completion, fast-tracking time-to-market and accelerating potential earnings inflection points.
Curious what turns that enthusiasm into a $30 fair value for Agenus? The narrative leans on specific revenue paths, margin shifts, and a punchy future earnings multiple. The exact mix driving that valuation might surprise you.
Result: Fair Value of $30 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the bullish Agenus narrative still leans heavily on successful late stage BOT/BAL trials and assumes the company avoids further funding strain or heavy shareholder dilution.
Find out about the key risks to this Agenus narrative.
Next Steps
With sentiment clearly split on Agenus, this is the moment to look through the numbers and stress test the story yourself using 3 key rewards and 6 important warning signs.
Looking for more investment ideas beyond Agenus?
Do not stop with Agenus. Use the Simply Wall Street Screener to uncover other stocks that fit your style before the next wave of opportunities moves without you.
- Spot potential future leaders early by scanning screener containing 20 high quality undiscovered gems that already show strong underlying fundamentals.
- Prioritize resilience by focusing on companies in the 79 resilient stocks with low risk scores that pair lower risk scores with more measured profiles.
- Build a more dependable income stream by reviewing the 8 dividend fortresses that offer 5%+ yields with an emphasis on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com